Bayer’s Supreme Court Victory and New Herbicide Clear a Path to Restructuring, But a Stretched Rally Gives Pause
Published on 07/08/2026 at 07:44 | Redaktion boerse-global.de
The US Supreme Court’s 7–2 ruling on Tuesday has fundamentally altered the legal landscape for Bayer’s Roundup litigation, stripping state-level plaintiffs of a key argument and removing what many analysts viewed as the biggest overhang on the stock. The decision, which affirms that federal pesticide labels approved by the Environmental Protection Agency supersede state failure-to-warn claims, is expected to derail thousands of outstanding cases. The EPA has consistently maintained that glyphosate is unlikely to cause cancer when used correctly, and the ruling now aligns federal and judicial interpretation.
Investors have already priced in much of the good news. Bayer’s stock has surged 42.7% over the past month alone to €50.78, nearly doubling from a year ago. The rally briefly touched a 52-week high of €53.86 on 3 July 2026. But technical indicators are flashing caution: the Relative Strength Index stands at 74.3, deep in overbought territory. After such a rapid ascent, short-term consolidation looks likely, and the stock slipped 0.39% on Tuesday as traders took some profits.
Beyond the courtroom, Bayer is pressing forward with operational and strategic shifts. The EPA has granted federal registration to Convintro, a new herbicide built on a novel mode of action aimed at tackling resistant weeds such as pigweed in corn and soybeans. Commercial launch is planned for the 2027 growing season, pending state-level approvals. Separately, the company has already begun carving out its US glyphosate business: since the start of the month, a newly formed entity called Ruveon LLC, based in St. Louis, is running all operational and pricing decisions independently.
Should investors sell immediately? Or is it worth buying Bayer?
Analysts see the legal tailwinds as a potential catalyst for deeper structural change. Berenberg’s Sebastian Bray raised his price target from €40.50 to €55.00, though he kept a Hold rating, citing the stock’s recent run. He pointed to three legal wins — the Supreme Court decision, a victory in the Durnell case, and a remand in Missouri — as clearing the way for Bayer to spin off or partially list its agriculture business under the working name “New Monsanto,” a move that would mirror BASF’s planned 2027 spin-off. JPMorgan and Goldman Sachs remain positive, with JPMorgan reiterating an Overweight rating and a €50 target.
A major settlement hearing that was meant to be the next milestone has been pushed back. Originally scheduled for early July, the court will now consider a proposed $7.25-billion Roundup settlement on 19 August 2026. Bayer’s management insists the delay is routine and does not affect the overall process.
Investors get their next update on 4 August 2026, when the company releases second-quarter earnings. The consensus forecast calls for full-year earnings per share of €4.39, and with legal risks receding and the restructuring narrative gaining momentum, the market will be watching closely to see whether management can translate the newfound clarity into concrete financial results.
Ad
Bayer Stock: New Analysis - 8 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
